tiprankstipranks
Analyst Profile
Followed by 319 other investors
.
Kristen Kluska

Kristen Kluska

Cantor Fitzgerald
Wall Street Analyst
Ranked #1,570 out of 8,047 Analysts on TipRanks (#2,800 out of 21,521 overall experts)

Success Rate

38%
28 out of 74 Profitable Transactions

Average Return

14.10%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Kristen Kluska's ratings since 2019 and opened each position for the duration of 1 Year:
37.84% of your transactions would have been profitable with an average return of 14.1%

Stock Rating Distribution

88Ratings
86.36% Buy
13.64% Hold
0.00% Sell
Distribution of Kristen Kluska's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Ocugen Inc
(OCGN)
Rating Type:Buy
Dates:Oct 09, 2020 - May 07, 2021
Gain:800.00%
The most profitable rating made by Kristen Kluska

Kristen Kluska's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
GW Pharma
Buy
Reiterated
0%
-39.90%
1
Yumanity Therapeutics
Buy
Reiterated
$80.00
(4748.48% Upside)
0%
-56.77%
5
BiomX
Buy
Reiterated
$19.00
(2429.96% Upside)
67%
-7.17%
3
Applied Genetic Technologies
Buy
Reiterated
$14.00
(3064.56% Upside)
0%
-32.75%
2
Taiwan Liposome Company
Buy
Reiterated
75%
+17.58%
4
Evogene
Buy
Initiated
$9.00
(696.46% Upside)
0%
-42.60%
1
uniQure
Buy
Reiterated
$66.00
(223.85% Upside)
0%
-28.85%
2
Ibio
Buy
Initiated
$3.00
(971.43% Upside)
0%
-69.80%
1
NightHawk Biosciences
Buy
Initiated
$22.00
(824.37% Upside)
0%
-68.30%
1
Lineage Cell Therapeutics
Buy
Initiated
$6.00
(282.17% Upside)
0%
-33.60%
1
List of latest recommendations made by Kristen Kluska. Click to expand and see Kristen Kluska's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More